Skip to content


May 2024

Luncolive Project

The page dedicated to the Luncolive project is now online!

Consult it to find out about the progress of this R&D project on LUNCOLIVE technology funded by the EIC accelerator.

Apr 2024

Orixha raises 4 million euros from the EIC Fund and Bpifrance

Lyon and Paris, April 10, 2024 – Orixha announces that it has raised 4 million euros from the European Innovation Council Fund and the French Tech Seed fund, managed on behalf of the French government France 2030 initiative by Bpifrance. This financing will enable Orixha to develop and validate in the clinic its total liquid ventilation technology, starting with resuscitated cardiac arrest patients in critical care.    

Oct 2022

Orixha is laureate of the EIC Accelerator and receives 7,5 M€ for the LuncoLive project

With Luncolive, Orixha aims to promote the Liquid Ventilation as a new breakthrough technology in critical care.
Orixha announces that its Luncolive program has been selected by the European Innovation Council for a founding of 2.5 M€ and a capital investment of 5 M€, in order to improve the survival of post-cardiac arrest patients. This will allow to validate the clinical benefit of the Vent2Cool Solution in post-cardiac arrest syndrome and to explore and developp new medical applications in critical care.

Mar 2022

Orixha won the first prize for innovation at Medi'Nov Salon in Lyon

On march 31st, Orixha won the first prize of Innovation at Medi’Nov salon 2022. This competition was organized by the region Auvergne-Rhône-Alpes in France.

Nov 2021

Orixha raises 2 millions euros for the development of the Vent2Cool solution

Orixha just annonced a foundraising of 2 million euros from Angels SantéErganeo and its industrial partners : InfiplastOEM Development et Activation. This first round will allow to finalize the medical device Vent2Cool before starting the first clinical trial in cardiac arrest patients.

Sept 2021

Orixha receives the financial support of "Programme d'Investissement d'Avenir" after being selected at the I-Nov